Christopher Lee, MD; Alvaro Martinez, MD; Daniel Kim, MD, MBA; Steven E. Finkelstein, MD; and Dwight E. Heron, MD, MBA, FACRO, FACR, discuss how genomic and genetic research is revolutionizing our understanding of prostate cancer risk, progression, personalized treatment strategies, and potential targeted interventions by identifying specific genetic markers, inherited mutations, and molecular pathways that influence disease development and patient outcomes.
EP. 4: CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.